Closing the data loop in AI-driven drug discovery
AI is increasingly used in drug discovery to identify and optimize chemical compounds, aiming to reduce the high costs and failure rates of clinical trials. However, the industry faces physical bottlenecks in labs and a critical need for higher-quality, integrated data to move beyond predictive design.
Why it matters
Improving the efficiency of drug discovery could significantly lower pharmaceutical costs and accelerate the delivery of life-saving treatments to patients.
AI is identifying new therapeutics targets faster than ever. But this speed is exposing physical bottlenecks in the lab, and a need for better data.
Drug discovery is a high-cost, high-risk endeavor that is under growing pressure from a market increasingly defined by first-mover advantage.
Since the 1950s, the cost of developing new pharmaceuticals has roughly doubled every nine years—a phenomenon known as Eroom’s Law . Today, bringing a new drug to market takes an average of 10-15 years and costs anywhere from $1 billion to $2.5 billion , with failure rates upward of 90%.
AI has become the pharmaceutical industry’s biggest bet on bringing success rates up and timelines down. The faster drug companies can identify, test, and optimize new chemical compounds, the lower the risk of costly failures later in development.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in